Welcome to our dedicated page for Illumina SEC filings (Ticker: ILMN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Illumina SEC filings document the company’s genomics technology business, financial results, governance and capital actions. Form 8-K reports cover quarterly and annual operating results, preliminary financial updates, share repurchase authorization, management and board changes, and Regulation FD disclosures.
The filing record also includes definitive proxy materials for annual meeting matters, director elections, compensation and shareholder voting. Material-event filings document completed acquisition activity, including the purchase of SomaLogic and Sengenics aptamer-based and functional proteomics assets, along with exhibits, common-stock repurchase disclosures and other capital-structure records.
Frances Arnold reported proposed insider sales of Common Stock under a Form 144 notice. The filing lists prior dispositions and restricted shares vesting under registered plans.
The filing shows recent dispositions of 5,000 shares on 05/28/2026 for $780,650, 3,000 shares on 05/22/2026 for $435,076.08, and 1,000 shares on 05/22/2026 for $145,072.06. It also lists restricted stock vesting entries of 1,175, 322, and 1,503 shares on their respective vesting dates.
ILLUMINA, INC. reported that private investment funds advised by Corvex Management LP, entities associated with director Keith A. Meister, executed a series of indirect open-market sales of common stock. Across May 28–29 and June 1, the Corvex Funds sold an aggregate 669,596 shares at weighted-average prices generally between about $147.50 and $165.50 per share, as detailed in multiple price ranges.
The filing states that both Corvex and Mr. Meister disclaim beneficial ownership of these securities except to the extent of their pecuniary interest. The Corvex Funds also terminated equity swaps that had provided economic exposure comparable to 368,744 shares. On termination of 24,562 notional shares, the swaps counterparty paid the Corvex Funds $3,841,496.80 based on $156.40 per share, offset by $2,525,464.84 reflecting a $102.82 per-share cost, with the swap exercise and related stock purchases deemed exempt under Rule 16b-6(b).
ILLUMINA, INC. Chief Legal Officer Scott M. Davies reported an open-market sale of company stock. On May 29, 2026, he sold 615 shares of common stock at $160.00 per share. After this transaction, he directly holds 21,568 shares of Illumina common stock.
ILLUMINA, INC. Vice President and Chief Accounting Officer Scott D. Ericksen reported open-market sales of company common stock. He sold 1,500 shares on May 28, 2026 at $150.10 per share and 500 shares on May 29, 2026 at $160.00 per share. Following these transactions, he directly owns 14,446 shares of Illumina common stock.
Corvex Management LP reported sales of Common Stock of Illumina, Inc. The filing lists four open‑market transactions: 225,067 shares on 05/13/2026, 104,393 shares on 05/14/2026, 220,000 shares on 05/28/2026, and 50,540 shares on 05/29/2026. Each row includes the cash proceeds for that trade.
Illumina-related reporting person reported a sale of 1,500 shares of common stock on 05/28/2026 under a 10b5-1 plan, generating $225,150 in proceeds. The filing also lists 478 Restricted Stock Units and an Employee Stock Purchase Plan allocation of 500 shares.
ILLUMINA, INC. director Keith A. Meister filed an amended Form 4 to update his indirect holdings in the company’s common stock. The filing reports that entities associated with him hold 3,500,048 shares of Illumina common stock indirectly.
According to the disclosure, these shares are held for the accounts of certain private investment funds collectively referred to as the Corvex Funds, for which Corvex Management LP acts as investment adviser. The balance was adjusted to reflect transactions previously reported in a separate Form 4 filed on May 14, 2026, and this amendment itself does not report new purchases or sales.
Illumina reported a Form 144 notice indicating a proposed sale of 1,500 shares of Common Stock through Morgan Stanley Smith Barney LLC. The filing lists an aggregate amount of $225,255.00 and references 151,300,000 alongside a 05/28/2026 label. The securities identified include Restricted Stock Units (1,040) dated 11/05/2023 and Employee Stock Purchase Plan shares (460) dated 08/01/2014. The notice is a resale filing and reports the broker and methods for sale.
Illumina reported a Form 144 notice indicating a proposed sale of 1,500 shares of Common Stock through Morgan Stanley Smith Barney LLC. The filing lists an aggregate amount of $225,255.00 and references 151,300,000 alongside a 05/28/2026 label. The securities identified include Restricted Stock Units (1,040) dated 11/05/2023 and Employee Stock Purchase Plan shares (460) dated 08/01/2014. The notice is a resale filing and reports the broker and methods for sale.